NZ609594A - Eph receptor expression in tumor stem cells - Google Patents

Eph receptor expression in tumor stem cells

Info

Publication number
NZ609594A
NZ609594A NZ609594A NZ60959411A NZ609594A NZ 609594 A NZ609594 A NZ 609594A NZ 609594 A NZ609594 A NZ 609594A NZ 60959411 A NZ60959411 A NZ 60959411A NZ 609594 A NZ609594 A NZ 609594A
Authority
NZ
New Zealand
Prior art keywords
stem cells
receptor expression
tumor stem
eph receptor
eph
Prior art date
Application number
NZ609594A
Other languages
English (en)
Inventor
Angelo Luigi Vescovi
Elena Binda
Original Assignee
Stemgen S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stemgen S P A filed Critical Stemgen S P A
Publication of NZ609594A publication Critical patent/NZ609594A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NZ609594A 2010-10-01 2011-09-30 Eph receptor expression in tumor stem cells NZ609594A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10185930A EP2446895A1 (en) 2010-10-01 2010-10-01 EPH receptor expression in tumor stem cells
PCT/EP2011/067114 WO2012042021A1 (en) 2010-10-01 2011-09-30 Eph receptor expression in tumor stem cells

Publications (1)

Publication Number Publication Date
NZ609594A true NZ609594A (en) 2015-01-30

Family

ID=43856109

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ609594A NZ609594A (en) 2010-10-01 2011-09-30 Eph receptor expression in tumor stem cells

Country Status (11)

Country Link
US (1) US9078857B2 (enExample)
EP (2) EP2446895A1 (enExample)
JP (4) JP2013540117A (enExample)
KR (2) KR20130095286A (enExample)
AU (1) AU2011310109B2 (enExample)
CA (1) CA2813101C (enExample)
DK (1) DK2621513T3 (enExample)
ES (1) ES2616444T3 (enExample)
NZ (1) NZ609594A (enExample)
PL (1) PL2621513T3 (enExample)
WO (1) WO2012042021A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ611428A (en) 2010-12-08 2015-07-31 Stemcentrx Inc Novel modulators and methods of use
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
EP2733206A1 (en) * 2012-11-19 2014-05-21 Naroa LLC Method for the isolation for mammalian stem cells using EphA2 and uses thereof
JP2016540826A (ja) 2013-11-04 2016-12-28 ファイザー・インク 抗ｅｆｎａ４抗体−薬物コンジュゲート
RU2708075C2 (ru) 2014-04-30 2019-12-04 Пфайзер Инк. Конъюгаты анти-ртк7 антитело-лекарственное средство
WO2016092378A1 (en) * 2014-12-10 2016-06-16 Angelo Luigi Vescovi Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors
KR20180016391A (ko) 2015-05-08 2018-02-14 플로우조, 엘엘시 데이터 발견 노드
US11174484B2 (en) 2015-11-10 2021-11-16 B. G. Negev Technologies And Applications Ltd., At Ben- Gurion University Means and methods for reducing tumorigenicity of cancer stem cells
EP4129311A4 (en) * 2020-03-31 2024-06-12 Keio University Therapeutic agent using genome-edited pluripotent stem cell
WO2026022122A1 (en) * 2024-07-23 2026-01-29 Eos Research Sa Checkpoint inhibitors in the treatment of glioblastoma multiforme

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1682173A4 (en) * 2003-10-15 2007-10-31 Medimmune Inc EPHA2 VACCINE ON LISTERIA BASE
EP1778726A4 (en) * 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
US8343461B2 (en) * 2006-03-08 2013-01-01 Wake Forest University Health Sciences Molecular signature of cancer
BRPI0816094A2 (pt) * 2007-08-30 2015-03-03 Daiichi Sankyo Co Ltd Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.

Also Published As

Publication number Publication date
JP6523910B2 (ja) 2019-06-05
DK2621513T3 (en) 2017-03-06
AU2011310109A1 (en) 2013-05-02
EP2621513A1 (en) 2013-08-07
AU2011310109B2 (en) 2014-11-20
CA2813101A1 (en) 2012-04-05
PL2621513T3 (pl) 2017-06-30
EP2446895A1 (en) 2012-05-02
KR20160027106A (ko) 2016-03-09
JP2016094391A (ja) 2016-05-26
ES2616444T3 (es) 2017-06-13
WO2012042021A1 (en) 2012-04-05
US20120083454A1 (en) 2012-04-05
JP2020037579A (ja) 2020-03-12
JP2013540117A (ja) 2013-10-31
KR20130095286A (ko) 2013-08-27
US9078857B2 (en) 2015-07-14
JP2018048151A (ja) 2018-03-29
JP6618968B2 (ja) 2019-12-11
KR101719966B1 (ko) 2017-03-24
EP2621513B1 (en) 2016-12-28
CA2813101C (en) 2018-10-30

Similar Documents

Publication Publication Date Title
NZ609594A (en) Eph receptor expression in tumor stem cells
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
AU2018256508A1 (en) Individualized vaccines for cancer
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
MX2019008428A (es) Inhibidores de glucosilceramida sintasa.
MX2011007930A (es) Conjugados de insulina cristalina.
NZ584458A (en) Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
PH12012501782A1 (en) Phytocannabinoids in the treatment of cancer
MX2012003770A (es) Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia.
GB201309758D0 (en) Generation of neural stem cells from human trophoblast stem cells
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
PH12013501894A1 (en) Human tissue factor antibody and uses thereof
WO2011146568A8 (en) Predicting response to a her inhibitor
MX2012008958A (es) Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer.
NZ588435A (en) Use of a polypeptide with an angiotensin-converting enzyme 2 (ACE2) activity for treating tumours (with the exception of lung cancer)
MY170934A (en) Treatment of pain associated with dislocation of basal endometrium
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
MX365464B (es) Prodecimiento para preparar inhibidores de la glucosilceramida sintasa.
MX2015006004A (es) Inhibicion de celulas cancerosas resistentes a farmacos.
WO2008134752A3 (en) Methods and compositions for the treatment of cancer
EP2589605A4 (en) PEPTIDE INHIBITING TELOMERASE ACTIVITY, METHOD FOR PRODUCING THE SAME AND USE THEREOF
WO2011122859A3 (ko) 뇌종양의 재발 가능성 및 생존 예후 예측용 조성물 및 이를 포함하는 키트
SG179069A1 (en) Cancer stem cell-targeted and drug resistant cancer therapy
SG195170A1 (en) Methods of treating or preventing rheumatic disease

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2016 BY CPA GLOBAL

Effective date: 20150815

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2017 BY CPA GLOBAL

Effective date: 20160819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2018 BY CPA GLOBAL

Effective date: 20170817

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2019 BY CPA GLOBAL

Effective date: 20180816

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2020 BY SPRUSON + FERGUSON PTY LTD

Effective date: 20190927

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2021 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20200921

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2022 BY DENNEMEYER + CO.

Effective date: 20210921

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2023 BY DENNEMEYER + CO.

Effective date: 20220929

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2024 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20230918

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2025 BY DENNEMEYER ET CO

Effective date: 20240927

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 SEP 2026 BY DENNEMEYER + CO. SARL

Effective date: 20251006